160 related articles for article (PubMed ID: 36284226)
1. The potential key genes and pathways associated with Wilms tumor in quest of proper candidates for diagnostic and therapeutic purposes.
Bitaraf M; Mahmanzar M; Zafari N; Mohammadpour H; Vasei M; Moradi Matin L; Kajbafzadeh AM; Majidi Zolbin M
Sci Rep; 2022 Oct; 12(1):17906. PubMed ID: 36284226
[TBL] [Abstract][Full Text] [Related]
2. Using Elevated Cholesterol Synthesis as a Prognostic Marker in Wilms' Tumor: A Bioinformatic Analysis.
He Y; Cui X; Lin Y; Wang Y; Wu D; Fang Y
Biomed Res Int; 2021; 2021():8826286. PubMed ID: 33628817
[TBL] [Abstract][Full Text] [Related]
3. Increased expression of the insulin-like growth factor I receptor gene, IGF1R, in Wilms tumor is correlated with modulation of IGF1R promoter activity by the WT1 Wilms tumor gene product.
Werner H; Re GG; Drummond IA; Sukhatme VP; Rauscher FJ; Sens DA; Garvin AJ; LeRoith D; Roberts CT
Proc Natl Acad Sci U S A; 1993 Jun; 90(12):5828-32. PubMed ID: 8390684
[TBL] [Abstract][Full Text] [Related]
4. Expression and imprinting status of human PEG8/IGF2AS, a paternally expressed antisense transcript from the IGF2 locus, in Wilms' tumors.
Okutsu T; Kuroiwa Y; Kagitani F; Kai M; Aisaka K; Tsutsumi O; Kaneko Y; Yokomori K; Surani MA; Kohda T; Kaneko-Ishino T; Ishino F
J Biochem; 2000 Mar; 127(3):475-83. PubMed ID: 10731720
[TBL] [Abstract][Full Text] [Related]
5. Increased expression of the insulin-like growth factor-II gene in Wilms' tumor is not dependent on loss of genomic imprinting or loss of heterozygosity.
Wang WH; Duan JX; Vu TH; Hoffman AR
J Biol Chem; 1996 Nov; 271(44):27863-70. PubMed ID: 8910385
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive Analysis of lncRNA-Mediated ceRNA Crosstalk and Identification of Prognostic Biomarkers in Wilms' Tumor.
Zheng H; Li BH; Liu C; Jia L; Liu FT
Biomed Res Int; 2020; 2020():4951692. PubMed ID: 32149111
[TBL] [Abstract][Full Text] [Related]
7. Insulin-like growth factor II and WT1 transcript localization in human fetal kidney and Wilms' tumor.
Yun K; Fidler AE; Eccles MR; Reeve AE
Cancer Res; 1993 Nov; 53(21):5166-71. PubMed ID: 8221652
[TBL] [Abstract][Full Text] [Related]
8. Cadherins in Wilms' tumor: E-cadherin expression despite absence of WT1.
Baudry D; Cabanis MO; Patte C; Zucker JM; Pein F; Fournet JC; Sarnacki S; Junien C; Jeanpierre C
Anticancer Res; 2003; 23(1A):475-8. PubMed ID: 12680252
[TBL] [Abstract][Full Text] [Related]
9. Clinicopathological parameters and prognostic relevance of miR-21 and PTEN expression in Wilms' tumor.
Cui M; Liu W; Zhang L; Guo F; Liu Y; Chen F; Liu T; Ma R; Wu R
J Pediatr Surg; 2017 Aug; 52(8):1348-1354. PubMed ID: 28040201
[TBL] [Abstract][Full Text] [Related]
10. [Nephroblastoma (Wilms' tumor): cytogenetic and molecular biology principles].
Strohmeyer T
Klin Padiatr; 1993; 205(3):135-9. PubMed ID: 8394474
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive Analysis of a Long Noncoding RNA-Associated Competing Endogenous RNA Network in Wilms Tumor.
Zhang F; Zeng L; Cai Q; Xu Z; Liu R; Zhong H; Mukiibi R; Deng L; Tang X; Xin H
Cancer Control; 2020; 27(2):1073274820936991. PubMed ID: 32597194
[TBL] [Abstract][Full Text] [Related]
12. Loss of imprinting of IGF2 sense and antisense transcripts in Wilms' tumor.
Vu TH; Chuyen NV; Li T; Hoffman AR
Cancer Res; 2003 Apr; 63(8):1900-5. PubMed ID: 12702581
[TBL] [Abstract][Full Text] [Related]
13. Weighted gene co‑expression network analysis for identifying hub genes in association with prognosis in Wilms tumor.
Wang X; Song P; Huang C; Yuan N; Zhao X; Xu C
Mol Med Rep; 2019 Mar; 19(3):2041-2050. PubMed ID: 30664180
[TBL] [Abstract][Full Text] [Related]
14. MiR-155-5p exerts tumor-suppressing functions in Wilms tumor by targeting IGF2 via the PI3K signaling pathway.
Luo X; Dong J; He X; Shen L; Long C; Liu F; Liu X; Lin T; He D; Wei G
Biomed Pharmacother; 2020 May; 125():109880. PubMed ID: 32004974
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical expression of GLUT1 and its correlation with unfavorable histology and TP53 codon 72 polymorphism in Wilms tumors.
Rakheja D; Khokhar S; Mitui M; Cost NG
Pediatr Dev Pathol; 2012; 15(4):286-92. PubMed ID: 22483234
[TBL] [Abstract][Full Text] [Related]
16. Amplification and overexpression of CACNA1E correlates with relapse in favorable histology Wilms' tumors.
Natrajan R; Little SE; Reis-Filho JS; Hing L; Messahel B; Grundy PE; Dome JS; Schneider T; Vujanic GM; Pritchard-Jones K; Jones C
Clin Cancer Res; 2006 Dec; 12(24):7284-93. PubMed ID: 17189400
[TBL] [Abstract][Full Text] [Related]
17. Decreased E-cadherin expression correlates with higher stage of Wilms' tumors.
Safford SD; Freemerman AJ; Langdon S; Bentley R; Goyeau D; Grundy PE; Skinner MA
J Pediatr Surg; 2005 Feb; 40(2):341-8. PubMed ID: 15750927
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic changes encompassing the IGF2/H19 locus associated with relaxation of IGF2 imprinting and silencing of H19 in Wilms tumor.
Taniguchi T; Sullivan MJ; Ogawa O; Reeve AE
Proc Natl Acad Sci U S A; 1995 Mar; 92(6):2159-63. PubMed ID: 7534414
[TBL] [Abstract][Full Text] [Related]
19. Identification of the potential novel biomarkers as susceptibility gene for Wilms tumor.
Liu L; Song Z; Gao XD; Chen X; Wu XB; Wang M; Hong YD
BMC Cancer; 2021 Mar; 21(1):316. PubMed ID: 33765954
[TBL] [Abstract][Full Text] [Related]
20. Origins of DNA methylation defects in Wilms tumors.
Anvar Z; Acurzio B; Roma J; Cerrato F; Verde G
Cancer Lett; 2019 Aug; 457():119-128. PubMed ID: 31103718
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
